Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iain Ross Insider Profile
4 Followers
Iain Ross, Director at E Therapeutics, holds 1.70M shares in E Therapeutics (Ticker: GB:ETX). Most recently, Iain Ross ― shares of E Therapeutics on ― for an estimated value of ―.
Iain Ross E Therapeutics (ETX)Director
E Therapeutics (ETX)
Director
Not Ranked
Iain Ross has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Iain Ross does not currently own shares as a corporate insider.
A breakdown of Iain Ross's holdings
Insider Roles
Iain Ross does not currently hold a role as a corporate insider.
Roles that Iain Ross holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Iain Ross
Iain Ross's Trading History
List of latest transactions for each holding click on a transaction to see Iain Ross's performance on stock
You May Also Like
Iain Ross insider profile FAQ
What is the percentage of profitable transactions made by Iain Ross?
The percentage of profitable transactions made by Iain Ross is ―.
What is the average return per transaction made by Iain Ross?
The average return per transaction made by Iain Ross is ―.
What stocks does Iain Ross hold?
Iain Ross holds: GB:ETX stocks.
What was Iain Ross’s latest transaction?
Iain Ross latest transaction was an Uninformative Buy of ―.
What was Iain Ross's most profitable transaction?
Iain Ross’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Iain Ross's role in E Therapeutics?
Iain Ross's role in E Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.